Your browser doesn't support javascript.
loading
Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Kagoya, Yuki; Guo, Tingxi; Yeung, Brian; Saso, Kayoko; Anczurowski, Mark; Wang, Chung-Hsi; Murata, Kenji; Sugata, Kenji; Saijo, Hiroshi; Matsunaga, Yukiko; Ohashi, Yota; Butler, Marcus O; Hirano, Naoto.
Affiliation
  • Kagoya Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Guo T; Division of Immune Response, Aichi Cancer Center Research Institute, Nagoya, Japan.
  • Yeung B; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Saso K; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Anczurowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Wang CH; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Murata K; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Sugata K; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Saijo H; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Matsunaga Y; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Ohashi Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Butler MO; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hirano N; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Cancer Immunol Res ; 8(7): 926-936, 2020 07.
Article in En | MEDLINE | ID: mdl-32321775
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / Histocompatibility Antigens Class I / Histocompatibility Antigens Class II / Immunotherapy, Adoptive / Receptors, Chimeric Antigen / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Immunol Res Year: 2020 Document type: Article Affiliation country: Canada Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / Histocompatibility Antigens Class I / Histocompatibility Antigens Class II / Immunotherapy, Adoptive / Receptors, Chimeric Antigen / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Immunol Res Year: 2020 Document type: Article Affiliation country: Canada Country of publication: United States